Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML

Dror Sayar*, Yoav Burstein, Bela Bielorai, Amos Toren, Rina Dvir

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m 2. Two received two doses at diagnosis alone with conventional chemotherapy and one received one dose after relapse. GO was well tolerated and all three achieved remission. All were transplanted: one relapsed after 5 months and died of disease, one died a toxic death in remission due to pulmonary fibrosis, and one survived (41 months from diagnosis). In conclusion, GO was well tolerated in these young patients with evidence for efficacy.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalPediatric Blood and Cancer
Issue number1
StatePublished - 15 Jul 2010
Externally publishedYes


  • AML
  • CD33-positive AML
  • Gemtuzumab ozogamicin


Dive into the research topics of 'Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML'. Together they form a unique fingerprint.

Cite this